Recently, all members of China’s society have worked together to combat the 2019-nCoV virus. The epidemic has caused serious concern around the country, most notably regarding the progress of research on anti-viral drugs.On 2nd February, the China-Japan Friendship Hospital announced that it will lead a clinical research study on the use of remdesivir for the treatment of 2019-nCoV, which is expected to create new guidelinesonthe containment of novel coronavirus. Also, according to THE PAPER news, an application has been filed to begin aCDEfor clinic trial of remdesivir as a potentially effective drug against novel coronavirus, asannounced on the website of the Center for Drug Evaluation (CDE).
On 3rd February, ABA Chemicals
said that its subsidiary,Puyi Chemical, is a leading supplier of the key intermediates,atazanavirand darunavir, as well as the earliest bio-enzyme process developer in China. Atazanavirand darunavir are both currently on the list of nine anti-viral drugs officially recommended in China.
On 25th January, a joint research team from the Shanghai Institute of MateriaMedicaatthe Chinese Academy of Sciences and ShanghaiTech Universityannounced the discovery of several conventional drugs and traditional Chinese medicines with remedial effects against novel pneumonia. These include 30 types of drugs, active natural substances and traditional Chinese medicines that may be therapeutic against the 2019-nCoV virus. These conventional drugs and traditional Chinese medicines will be considered for use during the course of clinic treatment onpatients infected with 2019-nCoV.These drugs include atazanavir and darunavir.
ABA Chemicals is mainly engaged in the research, production and marketing of pesticide intermediates, specialty chemicals and pharmaceutical intermediates as a comprehensive chemical company while focusing on fine chemicals. It is also a custom manufacturer in China of premium pharmaceutical and pesticide intermediates, andis one of the country’s fine chemical industry leader. In February 2016, ABA Chemicals acquired 100% of stakes in Shanghai Puyi Chemical.
Founded in 2008, Puyi Chemical is a technology-driven chemical supplier. Yihui Biotech, whose controlling share is held by Puyi Chemical, is a leading Chinese bio-enzyme research and production company. Yihui Biotech is in possession of over 1,000 genetically-engineered enzymes. At present, Puyi Chemical’s chemical product portfolio covers APIs, including alfacalcidol and calcitriol, as well as pharmaceutical intermediates, such asatazanaviranddarunavir, along with amino acids that includetert-leucine andL-norvaline. Puyi Chemical is the largest atazanavir vendor in China.
With the ongoing comprehensive joint research studiesin 2019-nCoV, which are more depth andsupported by the whole of society, the emergence of targeted drugsis expected soon, which will effectively contain the epidemic as early as possible.